Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan ; volume:15 ; number:1 ; day:20 ; month:10 ; year:2015 ; pages:1-9 ; date:12.2015
BMC cancer ; 15, Heft 1 (20.10.2015), 1-9, 12.2015
- Creator
-
Kim, Seung Tae
- Contributor
-
Ahn, Tae Jin
Lee, Eunjin
Do, In-Gu
Lee, Su Jin
Park, Se Hoon
Park, Joon Oh
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
Kim, Suk Hyeong
Lee, Jeeyun
Kim, Hee Cheol
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1759-y
- URN
-
urn:nbn:de:1111-2016110616828
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
16.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Seung Tae
- Ahn, Tae Jin
- Lee, Eunjin
- Do, In-Gu
- Lee, Su Jin
- Park, Se Hoon
- Park, Joon Oh
- Park, Young Suk
- Lim, Ho Yeong
- Kang, Won Ki
- Kim, Suk Hyeong
- Lee, Jeeyun
- Kim, Hee Cheol
- SpringerLink (Online service)
Other Objects (12)
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study